Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

in the effort to create a vaccine. Will their partnership lead to a new model for drug development that accelerates medical innovation? Here’s Afeyan again: ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Other fact-checking organizations have debunked the claim; Reuters and AFP have also fact-checked similar claims that circulated in 2022 and 2023 ...

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...